Shares of bioMerieux (OTCMKTS:BMXMF - Get Free Report) traded down 2.3% during mid-day trading on Tuesday . The stock traded as low as $145.64 and last traded at $145.64. 1,504 shares changed hands during trading, an increase of 14,865% from the average session volume of 10 shares. The stock had previously closed at $149.14.
Analyst Upgrades and Downgrades
Separately, Royal Bank Of Canada lowered shares of bioMerieux from a "moderate buy" rating to a "hold" rating in a research note on Wednesday, May 7th.
View Our Latest Stock Analysis on BMXMF
bioMerieux Stock Performance
The firm's 50 day moving average price is $142.01 and its 200-day moving average price is $131.13. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.29 and a current ratio of 2.20.
About bioMerieux
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider bioMerieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMerieux wasn't on the list.
While bioMerieux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access